Researchers have identified a significant therapeutic vulnerability in triple-negative breast cancer (TNBC) cases characterized by the loss of one copy of the DNA ligase I (LIG1) gene. This genetic alteration, often found in tumors carrying TP53 mutations, is associated with increased resistance to standard platinum-based chemotherapy. By uncovering the specific molecular pathways that drive this resistance, investigators have demonstrated in preclinical models that combining existing pharmacological agents can successfully neutralize these tumor cells, offering a potential path forward for more precise treatment strategies.
The findings, published in the journal Molecular Cancer Therapeutics, suggest that LIG1 status could serve as a vital biomarker for patient stratification in future clinical trials.
Understanding the Role of LIG1 in DNA Repair
The research team focused on the compensatory mechanisms that these cells employ to survive.
Molecular Mechanisms of Platinum Resistance
The study highlights that TNBC tumors with TP53 mutations and LIG1 loss exhibit a distinct molecular profile. When coupled with the loss of LIG1, these tumors demonstrate a heightened capacity to bypass the damage typically induced by chemotherapy.
In animal models, the application of drug combinations—designed to block these compensatory survival pathways—resulted in a marked reduction in tumor volume. These results provide a proof-of-concept that pharmacological intervention can bypass the resistance conferred by the LIG1 deficit.
Implications for Clinical Stratification and Future Trials
By incorporating LIG1 status into the diagnostic workflow, clinicians may eventually be able to predict which patients are likely to be resistant to platinum-based therapies before treatment begins.
Have you found this analysis helpful? Please share this article with your professional network or leave a comment below to join the discussion on the future of precision oncology.
Keep reading